Silybum marianum(milk thistle) belongs to the compositea family. The main active component of the plant is silimarin. In recent years, the therapeutic effects of silimarin in treating cirrhosis, hepatitis B, liver toxicosis and cancers have been investigated, and its role as a maintenance and recovering agent for hepatocytes in liver diseases has been reported. The aim of this research was to determine the effect of the herbal medicine Livimarin used during the 3 critical days of mouse development to experimentally assess any potential teratogenicity. In this experimental study, 40 NMRI mice strain were grouped into control and the experimental 1, 2 and 3. Considering the maximum human dose of Livomarin which is 6 capsules per day, each containing 175 mg, 3 doses of Livomarin were applied orally in days 7, 8 and 9 of gestation. These included the maximum daily human dose in mice (0.48 mg Livomarin, experimental 1), quarter of a capsule (44 mg Livomarin, experimental 2) and half a capsule (88 mg Livomarin, experimental 3). Our findings indicated that the oral administration of the aforementioned doses of the drug had no effect on the morphological and morphometrical parameters such as weight, length and curvature of fetuses and their limb buds, neither on the different tissues examined microscopically as compared to the controls. However, some effects such as a significant increase in the number of renal tubules and placental blood vessels were observed in the experimental groups 2 and 3. The number of Haufboer cells in placenta was also increased significantly (p<0.05) in the experimental group 3. Based on theses findings, it is concluded that using Livomarin during these 3 critical days of mice development will not cause any embryonic or placental abnormalities in the NMRI mice strain.